Glycopyrronium Bromide Strandhaven (Glycopyrronium Bromide)

Glycopyrronium bromide is employed in several clinical contexts where reduction of secretions or smooth‑muscle relaxation is desired.

• Management of excessive oral secretions (sialorrhea) in neurological conditions.
• Pre‑operative reduction of respiratory secretions to facilitate anesthesia.
• Treatment of hyperhidrosis (excessive sweating) of the palms and soles.
• Adjunct therapy for chronic obstructive pulmonary disease (COPD) to improve airway patency.
• Off‑label use for certain gastrointestinal motility disorders under specialist supervision.

Side effects of glycopyrronium bromide vary in frequency and severity.

Common

• Dry mouth or reduced salivation.
• Constipation or reduced gastrointestinal motility.
• Blurred vision or difficulty focusing.
• Urinary retention or difficulty voiding.
• Elevated heart rate (tachycardia).

Serious

• Severe allergic reactions such as rash, itching, swelling, or anaphylaxis.
• Marked hypotension or cardiovascular collapse.
• Acute angle‑closure glaucoma.
• Persistent urinary retention requiring catheterisation.
• Severe constipation leading to bowel obstruction.

When considering glycopyrronium bromide, several safety considerations should be reviewed.

• Assess for a history of glaucoma, especially narrow‑angle type, before initiating therapy.
• Evaluate renal and hepatic function, as impairment may affect drug clearance.
• Use cautiously in patients with cardiovascular disease or uncontrolled tachyarrhythmias.
• Monitor for signs of urinary retention, particularly in men with prostatic hypertrophy.
• Educate patients about the risk of dry mouth and advise on adequate hydration.
• Avoid abrupt discontinuation in patients who have been on long‑term therapy to reduce withdrawal effects.

Glycopyrronium bromide may interact with other medications, influencing its safety profile.

Avoid

• Concurrent use with other anticholinergic agents (e.g., atropine, scopolamine) that may exacerbate anticholinergic burden.
• Combination with drugs that prolong the QT interval, increasing cardiac risk.

Use with caution

• Beta‑adrenergic agonists (e.g., albuterol) as additive cardiovascular effects may occur.
• Medications that affect renal excretion such as certain diuretics.
• Opioids, because reduced gastrointestinal motility may enhance constipation.
• Antihistamines with anticholinergic properties, which can increase dry mouth and urinary retention.